Latest Breaking News On - Ret positive - Page 1 : comparemela.com

Expert oncologist Benjamin P. Levy, MD, shares his excitement for an upcoming program centered on recent data with selpercatinib versus pembrolizumab in patients with non-small cell lung cancer following ESMO 2023.

Randomized phaseFirst line selpercatinib versus pembrolizumabPositive non small cell lung cancerNon small cell lung cancerLung cancerRet fusionRet mutationRet positiveChemo ioLoxo 292Esmo 2023Esmo annual meetingNovel therapyTargeted therapy